Core Viewpoint - The Hang Seng Index Company announced the inclusion of InnoCare Pharma (03696) into the Hang Seng Composite Index, effective from March 9, 2026, following a quarterly review [1] Group 1: Index Inclusion - InnoCare Pharma will be added to the Hang Seng Composite Index as part of the quarterly review results announced on February 13, 2025 [1] - The changes will be implemented after market close on March 6, 2026, and will affect the eligible stocks for the Hong Kong Stock Connect [1] - According to CICC's research report, InnoCare Pharma meets various criteria including market capitalization, liquidity, and listing duration, making it a candidate for inclusion in the Stock Connect [1] Group 2: Strategic Collaboration - On February 10, InnoCare Pharma announced a strategic collaboration with Kanghong Pharmaceutical for drug development [1] - The collaboration will focus on multiple projects in the central nervous system and autoimmune diseases, leveraging AI-enabled innovative drug development [1] - Under the agreement, InnoCare Pharma is expected to receive research funding support of up to several tens of millions of Hong Kong dollars for each project [1]
英矽智能(03696)获纳入恒生综合指数 有望成为港股通标的